Profitability Ratios
| Ratio |
Value |
| GP Margin |
93.0% |
| EBIT Margin |
-116.1% |
| EBITDA Margin |
-108.4% |
| Operating Margin |
-130.7% |
| Pretax Margin |
-127.9% |
| Cont. Ops Margin |
-125.4% |
| Net Margin |
-125.4% |
| Bottom Line Margin |
-125.4% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
4.21 |
| Quick Ratio |
4.21 |
| Solvency Ratio |
-0.356 |
| Cash Ratio |
0.67 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.10 |
| Forward PEG |
0.10 |
| Price/Book |
3.95 |
| Price/Sales |
3.91 |
| Price/FCF |
-7.94 |
| Price/Op Cash Flow |
-13.25 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.7162 |
| Debt/Equity |
3.1067 |
| Debt/Capital |
0.7565 |
| Long-Term Debt/Capital |
0.6347 |
| Financial Leverage |
4.34 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.33 |
| Operating Cash Flow Ratio |
-0.397 |
| Operating Cash Flow/Sales |
-29.5% |
| Free Cash Flow/Operating Cash Flow |
166.9% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-1.80 |
| Interest Coverage |
-11.1117 |
| Short-Term Operating Cash Flow Coverage |
-0.63 |
| Operating Cash Flow Coverage |
-0.10 |
| Capital Expenditure Coverage |
-1.49 |
| Dividend + Capital Expenditure Coverage |
-1.49 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
3.06 |
| EPS |
-3.838 |
| Debt/Share |
9.7833 |
| Cash/Share |
8.85 |
| Book Value/Share |
3.03 |
| Tangible BV/Share |
3.03 |
| Equity/Share |
3.03 |
| Operating Cash Flow/Share |
-0.903 |
| Capital Expenditure/Share |
0.604 |
| FCF/Share |
-1.508 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
0.980 |
| Earnings Before Tax/EBIT |
0.979 |
| Price/Fair Value |
3.95 |
| Debt/Market Cap |
0.5605 |
| Effective Tax Rate |
2.0% |
| Enterprise Value Multiple |
-5.99 |
ENTA - Enanta Pharmaceuticals, Inc.